Iguratimod, a Disease-Modifying Anti-Rheumatic Drug, Inhibits Osteoclastogenesis and Bone Resorption through Suppression of the Nuclear Factor of Activated T Cells Signaling Pathway
暂无分享,去创建一个
Keiichi Tanaka | M. Mikami | J. Shiota | A. Miura | H. Murao
[1] F. Wang,et al. Iguratimod (T-614) suppresses RANKL-induced osteoclast differentiation and migration in RAW264.7 cells via NF-κB and MAPK pathways. , 2016, International immunopharmacology.
[2] Keiichi Tanaka,et al. Iguratimod for the treatment of rheumatoid arthritis in Japan , 2015, Expert review of clinical immunology.
[3] K. Takagishi,et al. Efficacy of the clinical use of iguratimod therapy in patients with rheumatoid arthritis , 2015, Modern rheumatology.
[4] H. Aburatani,et al. Global epigenomic analysis indicates protocadherin-7 activates osteoclastogenesis by promoting cell-cell fusion. , 2014, Biochemical and biophysical research communications.
[5] Qiang Xu,et al. A Novel Disease-Modifying Antirheumatic Drug, Iguratimod, Ameliorates Murine Arthritis by Blocking IL-17 Signaling, Distinct from Methotrexate and Leflunomide , 2013, The Journal of Immunology.
[6] T. Mimori,et al. Concomitant iguratimod therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate: a randomized, double-blind, placebo-controlled trial , 2013, Modern rheumatology.
[7] H. Takayanagi,et al. New insights into osteoclastogenic signaling mechanisms , 2012, Trends in Endocrinology & Metabolism.
[8] T. Kodama,et al. Blimp1-mediated repression of negative regulators is required for osteoclast differentiation , 2010, Proceedings of the National Academy of Sciences.
[9] Keiichi Tanaka. Iguratimod (T-614): A novel disease modifying anti-rheumatic drug , 2009 .
[10] Y. Toyama,et al. MCP-1 expressed by osteoclasts stimulates osteoclastogenesis in an autocrine/paracrine manner. , 2009, Biochemical and biophysical research communications.
[11] C. Bao,et al. T-614, a novel immunomodulator, attenuates joint inflammation and articular damage in collagen-induced arthritis , 2008, Arthritis research & therapy.
[12] M. Sasamata,et al. Micro-CT imaging analysis for the effect of celecoxib, a cyclooxygenase-2 inhibitor, on inflammatory bone destruction in adjuvant arthritis rats , 2008, Journal of Bone and Mineral Metabolism.
[13] S. Hirono,et al. Treatment of arthritis with a selective inhibitor of c-Fos/activator protein-1 , 2008, Nature Biotechnology.
[14] Soo Young Lee,et al. MafB negatively regulates RANKL-mediated osteoclast differentiation. , 2007, Blood.
[15] H. Hashimoto,et al. Efficacy and safety of iguratimod compared with placebo and salazosulfapyridine in active rheumatoid arthritis: a controlled, multicenter, double-blind, parallel-group study , 2007, Modern rheumatology.
[16] Tak W. Mak,et al. Autoamplification of NFATc1 expression determines its essential role in bone homeostasis , 2005, The Journal of experimental medicine.
[17] Shi Wei,et al. IL-1 mediates TNF-induced osteoclastogenesis. , 2005, The Journal of clinical investigation.
[18] J. Woo,et al. The Calcineurin/Nuclear Factor of Activated T Cells Signaling Pathway Regulates Osteoclastogenesis in RAW264.7 Cells* , 2004, Journal of Biological Chemistry.
[19] T. Taniguchi,et al. The antirheumatic drug leflunomide inhibits osteoclastogenesis by interfering with receptor activator of NF-kappa B ligand-stimulated induction of nuclear factor of activated T cells c1. , 2004, Arthritis and rheumatism.
[20] K. Tanaka,et al. Inhibitory effects of an anti-rheumatic agent T-614 on immunoglobulin production by cultured B cells and rheumatoid synovial tissues engrafted into SCID mice. , 2003, Rheumatology.
[21] K. Calame,et al. Blimp-1 is required for the formation of immunoglobulin secreting plasma cells and pre-plasma memory B cells. , 2003, Immunity.
[22] Toshio Matsumoto,et al. Expression of RANK is dependent upon differentiation into the macrophage/osteoclast lineage: induction by 1alpha,25-dihydroxyvitamin D3 and TPA in a human myelomonocytic cell line, HL60. , 2003, Bone.
[23] H. Yoshikawa,et al. A novel anti-rheumatic drug, T-614, stimulates osteoblastic differentiation in vitro and bone morphogenetic protein-2-induced bone formation in vivo. , 2002, Biochemical and biophysical research communications.
[24] Hiroshi Takayanagi,et al. Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. , 2002, Developmental cell.
[25] K. Tanaka,et al. An anti-rheumatic agent T-614 inhibits NF-κB activation in LPS- and TNF-α-stimulated THP-1 cells without interfering with IκBα degradation , 2002, Inflammation Research.
[26] M. Kondo,et al. Inhibitory effect of T-614 on tumor necrosis factor-alpha induced cytokine production and nuclear factor-kappaB activation in cultured human synovial cells. , 2001, The Journal of rheumatology.
[27] K. Tanaka,et al. Synthesis and antiinflammatory activity of 7-methanesulfonylamino-6-phenoxychromones. Antiarthritic effect of the 3-formylamino compound (T-614) in chronic inflammatory disease models. , 2000, Chemical & pharmaceutical bulletin.
[28] Keiichi Tanaka,et al. A new anti-rheumatic drug, T-614, effectively suppresses the development of autoimmune encephalomyelitis , 1998, Journal of Neuroimmunology.
[29] K. Tanaka,et al. Pharmacological studies of the new antiinflammatory agent 3-formylamino-7-methylsulfonylamino-6-phenoxy-4'-1-benzopyran-4-o ne. 2nd communication: effect on the arachidonic acid cascades. , 1992, Arzneimittel-Forschung.
[30] K. Tanaka,et al. Pharmacological studies of the new antiinflammatory agent 3-formylamino-7-methylsulfonylamino-6-phenoxy-4H-1-benzopyran-4-o ne. 1st communication: antiinflammatory, analgesic and other related properties. , 1992, Arzneimittel-Forschung.
[31] 中尾 彰宏. RANKL-stimulated TNFα production in osteoclast precursor cells promotes osteoclastogenesis by modulating RANK signaling pathways , 2008 .
[32] I. Wicks,et al. Interleukin-6 modulates production of T lymphocyte-derived cytokines in antigen-induced arthritis and drives inflammation-induced osteoclastogenesis. , 2006, Arthritis and rheumatism.
[33] Keiichi Tanaka,et al. Synthesis and Antiinflammatory Activity of 7-Methanesulfonylamino-6-phenoxychromones. Antiarthritic Effect of the 3-Formylamino Compound (T-614) in Chronic Inflammatory Cisease Models , 2000 .
[34] Keiichi Tanaka,et al. Pharmacological studies on T-614, a novel antiinflammatory agent: effect on type II collagen-induced arthritis in DBA/1J mice and spontaneous arthritis in MRL/I mice , 1993 .